Michael Ulz
Stock Analyst at Morgan Stanley
(4.66)
# 168
Out of 5,242 analysts
108
Total ratings
61.76%
Success rate
28.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AARD Aardvark Therapeutics | Downgrades: Underweight | $7 → $3 | $4.51 | -33.48% | 3 | May 15, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $130 → $140 | $100.67 | +39.07% | 7 | May 5, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $95 → $130 | $75.78 | +71.55% | 9 | Apr 21, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Upgrades: Overweight | $78 → $100 | $75.54 | +32.38% | 8 | Apr 21, 2026 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $21 → $15 | $8.06 | +86.10% | 9 | Mar 25, 2026 | |
| CABA Cabaletta Bio | Maintains: Overweight | $14 → $13 | $3.69 | +252.30% | 7 | Mar 24, 2026 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $50 → $47 | $17.37 | +170.58% | 4 | Mar 3, 2026 | |
| GUTS Fractyl Health | Downgrades: Equal-Weight | $8 → $2 | $0.92 | +117.39% | 3 | Jan 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $495 → $408 | $300.51 | +35.77% | 13 | Jan 30, 2026 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $20 → $25 | $8.90 | +180.90% | 3 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $98 → $102 | $30.68 | +232.46% | 4 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $25 | $6.49 | +285.21% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $3.70 | +440.54% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $2.10 | +233.33% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $8.46 | +219.15% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $0.9841 | +1,932.31% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.11 | +1,346.95% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $140 | $8.58 | +1,531.70% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $5.54 | -45.85% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $9.03 | +232.23% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $23.71 | +237.41% | 3 | Nov 3, 2017 |
Aardvark Therapeutics
May 15, 2026
Downgrades: Underweight
Price Target: $7 → $3
Current: $4.51
Upside: -33.48%
Mirum Pharmaceuticals
May 5, 2026
Maintains: Overweight
Price Target: $130 → $140
Current: $100.67
Upside: +39.07%
Ionis Pharmaceuticals
Apr 21, 2026
Maintains: Overweight
Price Target: $95 → $130
Current: $75.78
Upside: +71.55%
Arrowhead Pharmaceuticals
Apr 21, 2026
Upgrades: Overweight
Price Target: $78 → $100
Current: $75.54
Upside: +32.38%
Karyopharm Therapeutics
Mar 25, 2026
Maintains: Outperform
Price Target: $21 → $15
Current: $8.06
Upside: +86.10%
Cabaletta Bio
Mar 24, 2026
Maintains: Overweight
Price Target: $14 → $13
Current: $3.69
Upside: +252.30%
Dyne Therapeutics
Mar 3, 2026
Maintains: Overweight
Price Target: $50 → $47
Current: $17.37
Upside: +170.58%
Fractyl Health
Jan 30, 2026
Downgrades: Equal-Weight
Price Target: $8 → $2
Current: $0.92
Upside: +117.39%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Equal-Weight
Price Target: $495 → $408
Current: $300.51
Upside: +35.77%
Kyverna Therapeutics
Dec 4, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $8.90
Upside: +180.90%
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $30.68
Upside: +232.46%
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $6.49
Upside: +285.21%
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $3.70
Upside: +440.54%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $2.10
Upside: +233.33%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $8.46
Upside: +219.15%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $0.9841
Upside: +1,932.31%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.11
Upside: +1,346.95%
Jan 27, 2023
Maintains: Overweight
Price Target: $280 → $140
Current: $8.58
Upside: +1,531.70%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $5.54
Upside: -45.85%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $9.03
Upside: +232.23%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $23.71
Upside: +237.41%